Condition: Locally Advanced/Metastatic Solid Tumors · Sponsor: Shanghai Escugen Biotechnology Co., Ltd
This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.
This description comes directly from the study's public registry record.
Xiaoyan Xing, PhD · +86 21 5855 6098 · xingxiaoyan@escugen.com
Always discuss trial participation with your own doctor first.
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| The First Affiliated Hospital of Xi 'An Jiaotong University | Xi’an, Shanxi, China | Recruiting |
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06979674